Get the Stockscreener App
1.96
2.49%
-0.05
Pre-market:
1.96
Enveric Biosciences Inc stock is traded at $1.96, with a volume of 29,542.
It is down -2.49% in the last 24 hours and down -19.01% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$2.01
Open:
$1.9601
24h Volume:
29,542
Relative Volume:
0.08
Market Cap:
$2.73M
Revenue:
-
Net Income/Loss:
$-9.73M
P/E Ratio:
-0.0241
EPS:
-81.4762
Net Cash Flow:
$-7.67M
1W Performance:
+2.08%
1M Performance:
-19.01%
6M Performance:
-72.85%
1Y Performance:
-90.56%
1-Day Range:
$1.92
$1.99
1-Week Range:
$1.8601
$2.06
52-Week Range:
$1.82
$21.48
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.96 | 2.73M | 0 | -9.73M | -7.67M | -81.48 |
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
684.50 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enveric Biosciences Inc Stock (ENVB) Latest News
ENVB Q4'25 Earnings: EPS estimate is (55.80) USD - TradingView
Gilgamesh withdraws patent fight against Enveric after $1.2 billion AbbVie deal, CEO says key drug claims now uncontested - MSN
Enveric Biosciences (ENVB) Secures Trademark Registrations in Ca - GuruFocus
Enveric Biosciences announces withdrawal of petition against its patent — ENVB stock rises - MSN
Enveric Biosciences secures Canadian trademark registrations By Investing.com - Investing.com Canada
Enveric Biosciences announces registration of five trademarks - marketscreener.com
Enveric Biosciences Announces Registration of Five Trademarks - Business Wire
Bull Bear: Can Enveric Biosciences Inc sustain its profitabilityStock Surge & Short-Term Trading Alerts - baoquankhu1.vn
ENVB Forecast, Price Target & Analyst Ratings | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Patterns Watch: Is Enveric Biosciences Inc stock forming a cup and handle2025 Retail Activity & Verified Swing Trading Watchlists - baoquankhu1.vn
ENVB SEC FilingsEnveric Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VIX Spike: Is APREs ROE strong enoughWeekly Stock Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
ENVB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Can SUUN sustain earnings growthMarket Growth Summary & Weekly Return Optimization Plans - baoquankhu1.vn
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy - microdose.buzz
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent - Investing News Network
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Asianet Newsable
Enveric Biosciences announces withdrawal of PGR petition filed by Gilgamesh Pharmaceuticals against its patent - marketscreener.com
Biopharmaceutical company Enveric Biosciences announced today that Gilgamesh Pharmaceuticals has officially withdrawn its post-grant review request for a patent previously filed against Enveric Biosciences. - Bitget
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now UncontestedEnveric Biosciences (NASDAQ:ENVB) - Benzinga
Market Review: Does ARIS have declining or rising EPSMarket Movers & Reliable Breakout Forecasts - baoquankhu1.vn
Will Enveric Biosciences Inc. stock outperform Dow Jones index2025 Winners & Losers & Daily Stock Trend Watchlist - mfd.ru
MSN Money - MSN
Enveric Biosciences reports EB-003 receptor engagement assay data - Yahoo Finance
Is Enveric Biosciences Inc.’s ROE strong enoughGDP Growth & Growth Focused Stock Pick Reports - mfd.ru
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data - Investing News Network
Enveric’s lead drug candidate activates key pathways linked to depression relief - Investing.com Canada
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy - microdose.buzz
Enveric Biosciences (ENVB) stock: gains as EB-003 shows dual 5-HT₂A pathway activation - parameter.io
Enveric's EB-003 Assay Data Shows Dual 5-HTA Pathway Engagement; Stock Up - Nasdaq
Enveric Biosciences stock soars after revealing new data on lead drug candidate - Investing.com Australia
Enveric Stock Surges After Licensed Trademark Deal - timothysykes.com
Enveric Biosciences (ENVB) Reveals Promising Data on Lead Candidate EB-003 - GuruFocus
Enveric Advances Lead Drug With New Findings On Key Brain Receptor Signals - Benzinga
[EFFECT] Enveric Biosciences, Inc. SEC Filing - Stock Titan
US Market Recap: What makes Enveric Biosciences Inc stock attractive todayJuly 2025 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
What makes Enveric Biosciences Inc. stock attractive to growth funds2025 Technical Patterns & Expert Approved Trade Ideas - mfd.ru
Can Enveric Biosciences Inc. lead its sector in growthQuarterly Risk Review & Comprehensive Market Scan Insights - mfd.ru
Enveric Biosciences Nears Key Clinical Milestone with Novel Drug Candidate - AD HOC NEWS
Enveric Biosciences (ENVB) Files for Share Sale to Investors - GuruFocus
Why Enveric Biosciences Inc. stock remains on buy listsJuly 2025 Snapshot & Pattern Based Trade Signal System - mfd.ru
US Market Wrap: Is PEBK benefiting from innovation trendsMarket Volume Report & Daily Profit Maximizing Tips - baoquankhu1.vn
Enveric Biosciences Expands At-The-Market Equity Offering Capacity - The Globe and Mail
Growth Report: What is Enveric Biosciences Incs book value per shareWeekly Trade Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Can Enveric Biosciences Inc sustain its profitabilityJobs Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Analyst Calls: Is Enveric Biosciences Inc a good ESG investmentQuarterly Market Summary & Safe Capital Investment Plans - baoquankhu1.vn
Fed Meeting: Can Magnite Inc grow without external fundingJuly 2025 Reactions & Verified Momentum Watchlists - baoquankhu1.vn
Enveric Biosciences registers $1.35 million in new shares under ATM agreement - Investing.com UK
Enveric Biosciences registers $1.35 million in new shares under ATM agreement By Investing.com - Investing.com India
Enveric Biosciences Registers Additional Shares for ATM Offering - TradingView
Enveric Biosciences (NASDAQ:ENVB) Trading Down 7.4% – Should You Sell? - Defense World
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):